EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Plasma proteomics predicts pathological complete response and reveals LIF as a potential mediator of resistance to neoadjuvant immunochemotherapy in resectable NSCLC

Shoucheng Feng, Ziqing Feng, Songzuo Xie, Yuheng Zhou, Weizhen Sun, Nengqi Lin, Zhichao Lin, Qinglin Wang, Zerui Zhao, Yaobin Lin, Hao Long

Journal for ImmunoTherapy of Cancer · 2026-07 · 14 (7) · e015312

DOI: 10.1136/jitc-2026-015312 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 09.07.2026. Verfasst von Shoucheng Feng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key L…. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Lung Neoplasms, Proteomics, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Development Center for Medical Science and Technology National Health Commission of the People’s Republic of China, the Young Talents Program of Sun Yat-sen University Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neoadjuvant immunochemotherapy (nICT) is increasingly used for resectable non-small cell lung cancer (NSCLC), yet a substantial proportion of patients fail to achieve pathological complete response (pCR). Clinically scalable, minimally invasive biomarkers that predict response and point to actionable resistance mechanisms remain needed.

Methods

Pretreatment plasma samples collected prior to the first dose were profiled using the Olink proximity extension assay in a Sun Yat-sen University Cancer Center cohort (n=86), randomly split into a training set (n=65) and an internal validation set (n=21). Differentially abundant proteins associated with pCR were identified, and predictive models were developed using logistic regression, random forest, and extreme gradient boosting (XGBoost), followed by internal validation and independent external validation in the Jiangmen Central Hospital cohort (n=46). Survival associations were evaluated by Cox regression. Mechanistic analyses integrated tumor immunohistochemistry/multiplex immunofluorescence, bulk RNA sequencing with immune deconvolution, and functional validation in subcutaneous and orthotopic murine lung cancer models with pharmacologic leukemia inhibitory factor (LIF) blockade.

Results

Four candidate proteins (LIF, CXCL1, CX3CL1, and NT-3) showed modest single-marker discrimination for pCR (area under the curve (AUC), 0.611–0.673). Multiprotein models improved prediction, with XGBoost achieving the highest performance (training AUC=0.95; internal validation AUC=0.845 (95% CI 0.65 to 1.00); external validation AUC=0.801 (95% CI, 0.57 to 0.93)). SHapley Additive exPlanations analysis identified LIF as the dominant feature negatively associated with pCR probability. Elevated baseline plasma LIF was associated with inferior overall survival (HR=13.003; 95% CI 1.456 to 116.135; p=0.0217) and progression-free survival (HR=3.75; 95% CI 1.362 to 10.327; p=0.0105) after nICT. High LIF tumors exhibited reduced CD8 + T-cell infiltration and suppressed cytotoxic effector programs. In murine models, LIF blockade synergized with immunochemotherapy to enhance antitumor efficacy, restore CD8 + T-cell effector function, and mitigate T-cell exhaustion.

Conclusions

Baseline plasma proteomics shows promise for predicting pCR to nICT in resectable NSCLC and nominates LIF as a predictive, prognostic, and therapeutic candidate mediator of resistance. These findings warrant prospective validation and further investigation of LIF-targeted combination strategies in the neoadjuvant setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyLung NeoplasmsProteomicsCarcinoma, Non-Small-Cell LungLeukemia Inhibitory FactorImmunotherapyBiomarkers, TumorHumansPathologic Complete ResponseAnimalsFemaleDrug Resistance, NeoplasmMaleMiceMiddle Aged

Stichwörter der Autor:innen

BiomarkerImmune Checkpoint InhibitorImmunotherapyLung Cancer

Substanzen

Leukemia Inhibitory FactorLIF protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Thoracic Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-s…
  • Lung Cancer Research Center, Sun Yat-sen University, Guangzhou, China.
  • Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-s…
  • Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-s…
  • Department of Thoracic Surgery, Jiangmen Central Hospital, Jiangmen, China.

Förderung

  • the Development Center for Medical Science and Technology National Health Commission of the People’s Republic of China
  • the Young Talents Program of Sun Yat-sen University Cancer Center

Zitieren

APA

Feng, S., Feng, Z., Xie, S., Zhou, Y., Sun, W., Lin, N., Lin, Z., Wang, Q., Zhao, Z., Lin, Y., & Long, H. (2026). Plasma proteomics predicts pathological complete response and reveals LIF as a potential mediator of resistance to neoadjuvant immunochemotherapy in resectable NSCLC. Journal for ImmunoTherapy of Cancer, 14(7), e015312. https://doi.org/10.1136/jitc-2026-015312

Vancouver

Feng S, Feng Z, Xie S, Zhou Y, Sun W, Lin N, et al. Plasma proteomics predicts pathological complete response and reveals LIF as a potential mediator of resistance to neoadjuvant immunochemotherapy in resectable NSCLC. Journal for ImmunoTherapy of Cancer. 2026;14(7):e015312. doi:10.1136/jitc-2026-015312

BibTeX
@article{Feng2026,
  author = {Feng, Shoucheng and Feng, Ziqing and Xie, Songzuo and Zhou, Yuheng and Sun, Weizhen and Lin, Nengqi and Lin, Zhichao and Wang, Qinglin and Zhao, Zerui and Lin, Yaobin and Long, Hao},
  title = {Plasma proteomics predicts pathological complete response and reveals LIF as a potential mediator of resistance to neoadjuvant immunochemotherapy in resectable NSCLC},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {7},
  pages = {e015312},
  doi = {10.1136/jitc-2026-015312}
}
Kostenlos starten →